| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥103.7B | ¥31.7B | +227.1% |
| Operating Income | ¥0.2B | ¥-2.4B | +59.6% |
| Ordinary Income | ¥0.1B | ¥-2.3B | +23.0% |
| Net Income | ¥-0.7B | ¥-1.6B | +53.7% |
| ROE | -1.3% | -2.7% | - |
FY2025 Q1 results: Revenue 103.7B yen (YoY +227.1%), Operating Income 0.2B yen (prior period loss of 2.4B yen, turning to profit), Ordinary Income 0.1B yen (prior period loss of 2.3B yen, +23.0%), Net Income -0.7B yen (prior period loss of 1.6B yen, deficit narrowed by 53.7%). The dramatic revenue expansion of +227.1% was primarily driven by consolidation of Fascia Holdings and its subsidiaries, adding Minimally Invasive Medical Device Sales and Rental segments. Operating income turned positive at 0.2B yen from prior year loss of 2.4B yen, marking an inflection point toward profitability. However, net income remained in deficit at -0.7B yen due to tax expenses of 0.8B yen and interest expenses of 0.2B yen, though the loss narrowed by 53.7% YoY. Total assets expanded to 212.3B yen from 108.7B yen, reflecting the M&A-driven business scale expansion.
Revenue increased 72.0B yen YoY to 103.7B yen, driven primarily by the acquisition of Fascia Holdings and consolidation of its subsidiaries. The newly consolidated Minimally Invasive Medical Device Sales segment contributed 47.3B yen and Rental segment added 1.7B yen, together accounting for approximately 47.3% of total revenue. The existing Total Medical Solution segment grew from 2.9B yen to 48.1B yen (+1,572%), substantially driven by expanded scope following the M&A. Remote Image Diagnosis Service remained relatively stable at 2.1B yen (prior period 2.1B yen). The company incurred subsidiary acquisition-related costs of 56.2M yen, recorded as non-recurring expenses in segment profit adjustments.
Gross profit reached 13.8B yen with a gross margin of 13.3%, indicating a low-margin business model typical of medical device distribution. Cost of sales was 89.9B yen (86.7% of revenue). SG&A expenses totaled 13.6B yen (13.1% of revenue), nearly offsetting gross profit and resulting in an operating margin of only 0.2%. The thin operating margin of 16M yen demonstrates limited operating leverage despite the substantial revenue scale expansion.
Operating income improved from a loss of 2.4B yen to a profit of 0.2B yen, representing a turnaround of 2.6B yen. However, non-operating expenses of 0.2B yen, primarily interest expenses of 0.2B yen, reduced ordinary income to 0.1B yen. The gap between ordinary income (0.1B yen) and net income (-0.7B yen) of 0.8B yen was driven by an unusually high income tax expense of 0.8B yen, resulting in an effective tax rate exceeding 1,000% on the pre-tax income base. This abnormal tax burden appears related to timing differences or deferred tax adjustments associated with the M&A transaction and warrants close monitoring in subsequent quarters.
The financial structure reflects high leverage with total liabilities of 155.9B yen (73.4% of total assets) and equity of 56.5B yen (equity ratio 26.6%). Long-term loans increased to 45.0B yen, supporting the acquisition financing. Interest expense of 0.2B yen against operating income of 0.2B yen yields an interest coverage ratio of 0.94x, indicating that operating profit barely covers interest obligations.
This represents a revenue growth/profit recovery pattern, where external growth through M&A drove substantial revenue expansion while operating profitability turned positive, but net income remained negative due to high tax and interest burdens.
Remote Image Diagnosis Service generated revenue of 2.1B yen with operating income of 0.2B yen, maintaining a solid operating margin of 11.5%. This represents the company's most profitable segment on a margin basis and demonstrates the inherent strength of the recurring service business model.
Total Medical Solution recorded revenue of 48.1B yen with operating loss of 4.9M yen (margin -0.1%). This represents the largest segment by revenue share (46.4%), positioning it as the core business. However, the segment operates at near breakeven, reflecting competitive pressure and scale-building phase characteristics. The substantial YoY expansion reflects consolidation effects from the M&A transaction.
Rental segment contributed revenue of 1.7B yen with operating income of 0.05B yen (margin 3.1%). This newly consolidated segment adds a recurring revenue stream with modest but positive profitability.
Minimally Invasive Medical Device Sales, the second-largest segment, generated revenue of 47.3B yen with operating income of 0.4B yen (margin 0.9%). This segment accounts for 45.6% of total revenue but operates on thin margins typical of medical device distribution, where volume scale is prioritized over margin expansion. The low margin structure of both major segments (Total Medical Solution at -0.1% and Minimally Invasive Medical Device Sales at 0.9%) explains the consolidated operating margin compression to 0.2%.
The segment profit adjustment of -60.9M yen includes subsidiary acquisition-related costs of 56.2M yen, unallocated corporate expenses of 5.7M yen, and intersegment eliminations. The margin differential between Remote Image Diagnosis Service (11.5%) and the distribution-heavy segments (sub-1% range) highlights the business portfolio's mixed profitability profile.
[Profitability] ROE -1.3% deteriorated from prior year levels, reflecting net loss despite operating improvements. Operating margin of 0.2% represents minimal profitability after gross margin of 13.3% was largely absorbed by SG&A expenses of 13.1%. Net profit margin of -0.7% reflects the impact of abnormally high tax expenses and interest burden. The profitability structure indicates a low-margin, high-volume business model with limited operating leverage in the current phase. [Cash Quality] Cash and deposits of 68.8B yen provide strong liquidity coverage of short-term debt at 2.3B yen, yielding a cash-to-short-term-debt ratio of 29.9x. However, accounts receivable increased substantially to 65.0B yen, with days sales outstanding estimated at approximately 229 days, indicating extended collection periods that warrant monitoring for working capital efficiency. [Investment Efficiency] Total asset turnover of 0.49x (quarterly revenue annualized basis) reflects the asset-intensive nature following M&A integration. Inventory turnover requires improvement with inventory of 13.9B yen against quarterly COGS of 89.9B yen. [Financial Health] Equity ratio of 26.6% indicates high leverage, with debt-to-equity ratio of 2.76x reflecting aggressive financial structure. Current ratio of 155.2% and quick ratio of 140.9% demonstrate adequate short-term liquidity. Long-term loans of 45.0B yen constitute 28.9% of total liabilities, supporting acquisition financing. Interest coverage ratio of 0.94x remains below the safety threshold, as interest expense of 0.2B yen nearly equals operating income of 0.2B yen. The financial structure prioritizes growth through leverage while maintaining liquidity buffers.
Cash and deposits increased 21.1B yen YoY to 68.8B yen, with the expansion primarily reflecting acquisition-related financing rather than organic cash generation. The substantial increase in accounts receivable of 23.1B yen (from 41.9B yen to 65.0B yen) indicates working capital absorption, with collection efficiency requiring attention given the extended DSO of approximately 229 days. Trade payables increased 29.8B yen to 64.5B yen, demonstrating effective utilization of supplier credit and providing a natural working capital offset. Inventory increased from 0.2B yen to 13.9B yen, adding 13.7B yen to working capital requirements as newly consolidated businesses bring inventory-intensive operations. The balance sheet changes suggest that while liquidity position remains strong with cash coverage of short-term liabilities at 29.9x, the quality of working capital management requires improvement particularly in receivables collection. The increase in long-term loans to 45.0B yen and overall debt structure with D/E ratio of 2.76x indicates that acquisition financing has created interest burden of 0.2B yen quarterly, which must be covered by operating improvements. The interest coverage ratio of 0.94x demonstrates that current operating profitability barely supports the debt service requirements, highlighting the importance of margin expansion in subsequent periods.
Ordinary income of 0.1B yen versus operating income of 0.2B yen shows non-operating net loss of approximately 0.1B yen, primarily driven by interest expenses of 0.2B yen associated with acquisition financing. The interest burden represents a structural cost of the growth strategy through M&A. Non-operating income was minimal at 0.1B yen, indicating limited contribution from equity method investments or financial income sources. The gap between ordinary income (0.1B yen) and net income (-0.7B yen) of 0.8B yen stems entirely from income tax expense of 0.8B yen, creating an effective tax rate exceeding 1,000% on the minimal pre-tax profit base. This abnormally high tax burden likely reflects deferred tax adjustments, timing differences, or non-deductible expenses associated with the M&A transaction, representing a significant quality concern that requires clarification in subsequent reporting. The company recorded comprehensive income of -0.6B yen, with valuation differences on securities contributing a positive 0.1B yen, partially offsetting the net loss. The presence of non-controlling interests of 0.1B yen in both net income and comprehensive income reflects the consolidated structure following the Fascia Holdings acquisition. The provisional allocation of purchase price, with goodwill of 22.1B yen recorded subject to finalization, introduces potential adjustment risk in future periods. Overall earnings quality is compromised by the abnormal tax burden, thin operating margins, and significant goodwill position requiring ongoing impairment monitoring.
Full-year guidance projects revenue of 420.0B yen (YoY +95.4%), operating income of 4.6B yen, ordinary income of 3.8B yen, and EPS of 1.35 yen. Q1 revenue of 103.7B yen represents 24.7% progress toward the annual target, slightly below the standard 25% quarterly pace but essentially on track. Operating income of 0.2B yen represents only 4.3% progress against the 4.6B yen target, significantly below the 25% benchmark and indicating backend-weighted profit expectations. The guidance assumes substantial margin expansion and operating leverage realization in subsequent quarters, requiring both revenue scale benefits and cost efficiency improvements. The company projects full-year ordinary income of 3.8B yen, implying an 82.6% conversion rate from operating income, which assumes normalized non-operating expenses after absorbing M&A-related costs in Q1. Full-year EPS guidance of 1.35 yen on 5.922M shares outstanding implies net income of approximately 0.08B yen, representing a dramatic turnaround from Q1's -0.7B yen loss and requiring resolution of the abnormal tax situation observed in Q1. The company has not revised guidance this quarter, maintaining confidence in the integration progress and synergy realization timeline. Dividend forecast remains at 0.00 yen, with no mid-term payout planned, though separate disclosure indicates a potential year-end dividend of 17 yen subject to performance confirmation. The guidance outlook requires close monitoring given the Q1 profit progress lag, with particular focus on margin improvement trajectory, working capital management effectiveness measured by receivables collection acceleration, and normalization of the tax burden in subsequent quarters.
No dividend forecast is provided in the official full-year guidance, maintaining a 0.00 yen annual dividend projection. However, separate disclosure indicates a potential year-end dividend of 17 yen, subject to business performance confirmation. Against Q1's net loss of 0.7B yen (annualized EPS of -13.46 yen), any dividend payment would result in a negative payout ratio and rely entirely on existing cash reserves rather than earnings generation. With cash and deposits of 68.8B yen, the company maintains financial capacity to distribute dividends, with a potential 17 yen per share payout requiring approximately 1.0B yen (17 yen x 5.922M shares), representing only 1.5% of current cash holdings. The sustainability of shareholder returns depends critically on achievement of the full-year profit guidance, particularly the projected turnaround to positive net income of 0.08B yen. No share buyback activity is disclosed for the current period. The dividend policy appears contingent and performance-linked, with management maintaining flexibility to adjust based on integration progress and profitability realization. Investors should monitor subsequent quarter results for clarity on dividend execution likelihood, with particular focus on operating margin expansion, normalization of the abnormal tax burden observed in Q1, and working capital management improvements that would support cash generation capacity.
Integration execution risk from the Fascia Holdings acquisition remains elevated, with potential challenges in system integration, customer retention, operational coordination, and realization of projected synergies. The company recorded 56.2M yen in acquisition-related costs in Q1, and further integration expenses may pressure near-term margins. Successful consolidation of four newly added entities (Fascia Holdings, Form, Sincom, Chukyo Sanyo) requires effective management attention and execution capability, with delays potentially impacting the full-year profit guidance that assumes backend-weighted margin improvements.
Financial structure risk stems from high leverage with D/E ratio of 2.76x and interest coverage of only 0.94x, indicating that operating income barely covers interest obligations. Long-term debt of 45.0B yen supporting the acquisition creates quarterly interest expenses of approximately 0.2B yen, requiring sustained operating income growth to maintain adequate debt service coverage. Rising interest rate environments could further pressure profitability, and failure to achieve projected operating leverage would leave the company vulnerable to refinancing challenges when debt matures. The equity ratio of 26.6% provides limited buffer against asset value deterioration or operating setbacks.
Working capital and cash quality risk is evidenced by extended receivables collection with DSO estimated at 229 days, substantially longer than industry norms. Accounts receivable of 65.0B yen represents 62.7% of quarterly revenue, indicating significant cash conversion delay and potential collection challenges. Inventory increased dramatically to 13.9B yen with the new consolidated operations, requiring effective turnover management to avoid obsolescence risk in the medical device distribution segments. The combination of extended receivables and increased inventory absorbs substantial working capital, and deterioration in collection efficiency could stress liquidity despite current strong cash position. The abnormally high tax burden in Q1 (0.8B yen tax expense against 0.1B yen pre-tax income) requires resolution, as continuation of such effective tax rates would prevent achievement of full-year net income guidance and compromise shareholder return capacity.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE -1.3% substantially underperforms the industry median of 3.6% (2025-Q1), positioning the company in the bottom quartile. The negative ROE reflects net loss status while peers maintain positive profitability. Net profit margin of -0.7% compares unfavorably to industry median of 7.4%, indicating significant margin disadvantage requiring structural improvement. Operating margin of 0.2% also trails materially behind typical trading sector profitability, consistent with the company's positioning in the low-margin medical device distribution space.
Financial Health: Equity ratio of 26.6% falls significantly below industry median of 39.7%, indicating higher leverage relative to peers. The company's D/E ratio of 2.76x exceeds the industry financial leverage median of 2.39x, reflecting more aggressive capital structure adopted to finance the acquisition strategy. This positions the company as more financially leveraged than typical industry participants, with correspondingly higher financial risk profile.
Efficiency: Asset turnover of 0.49x (quarterly annualized) substantially exceeds the industry median of 0.21x, indicating superior asset utilization efficiency. This reflects the high-velocity nature of the distribution business model where inventory and receivables turn relatively rapidly despite the elevated DSO. Receivables turnover estimated at 229 days compares to industry median of 316.5 days, suggesting relatively better collection performance than peer median despite the extended absolute collection period. Payables turnover management shows effective supplier credit utilization.
Growth: Revenue growth of +227.1% YoY dramatically outpaces industry median growth of 3.8%, positioning the company as a high-growth outlier. However, this growth is primarily M&A-driven rather than organic, distinguishing it from peers' steady-state operations. The growth profile reflects transformation phase rather than normalized expansion.
※ Industry: Trading Sector (4 companies), Comparison: 2025-Q1 period, Source: Proprietary analysis
The company has executed a transformative acquisition strategy, expanding revenue base from 31.7B yen to 103.7B yen (+227.1%) through consolidation of Fascia Holdings and adding two major new segments (Minimally Invasive Medical Device Sales at 47.3B yen and Rental at 1.7B yen). This external growth strategy positions the company for substantial scale expansion with full-year revenue guidance of 420.0B yen, though realization depends on successful integration execution. Operating profitability inflection is evident with the turnaround from 2.4B yen loss to 0.2B yen profit, marking initial progress toward positive earnings despite razor-thin 0.2% operating margin. The profitability trajectory requires close monitoring as management projects backend-weighted margin expansion to achieve 4.6B yen full-year operating income, implying substantial quarter-over-quarter improvement from the current 4.3% progress rate.
The financial structure reflects aggressive leverage deployment with D/E ratio of 2.76x and interest coverage of only 0.94x, positioning financial risk as a key monitoring point. Long-term debt of 45.0B yen creates interest burden of approximately 0.2B yen quarterly, requiring sustained operating income growth to maintain adequate coverage ratios above 2.0x. The abnormal tax burden in Q1 (0.8B yen tax expense against 0.1B yen pre-tax income) represents a significant earnings quality concern requiring resolution, as continuation would prevent achievement of full-year net income guidance of 0.08B yen and compromise any potential shareholder returns.
Working capital management efficiency emerges as a critical performance driver, with DSO estimated at 229 days indicating extended collection cycles that absorb substantial cash despite overall strong liquidity position of 68.8B yen. Accounts receivable of 65.0B yen and inventory of 13.9B yen represent major working capital deployment requiring active management focus. Improvement in collection efficiency and inventory turnover would enhance cash generation quality and support the leveraged capital structure. The company's asset turnover of 0.49x exceeds industry median of 0.21x, demonstrating underlying operational efficiency advantages despite the working capital absorption, suggesting potential for cash flow improvement as integration matures and economies of scale realize.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.